MedTrace Logo

Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.

NCT07470593 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2026-03-17

No results posted yet for this study

Summary

Islet transplantation is associated with drastically improvement glucose control in people with type 1 diabetes. This treatment resulted in the disappearance of severe hypoglycemic events. However, its long-term effectiveness is limited by progressive loss of graft function. Currently, there is no standardized method to detect early dysfunction of the transplanted islets.

This study aims to determine whether a parameter derived from continuous glucose monitoring (CGM), Time in Tight Range (70-140 mg/dL), is associated with pancreatic islet grafts function.

The study hypothesis is that a decrease in Time in Tight Range reflects early loss of islet graft function.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

OTHER

Continuous glucose monitoring (CGM) with TITR measurement

Continuous glucose monitoring (CGM) with TITR measurement

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Luc RAKOTOARISOA, Dr · HOPITAUX UNIVERSITAIRES DE STRASBOURG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2029-12-15
Completion
2029-12-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07470593 on ClinicalTrials.gov